<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097274</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4131</org_study_id>
    <nct_id>NCT05097274</nct_id>
  </id_info>
  <brief_title>The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation.</brief_title>
  <acronym>GENPET</acronym>
  <official_title>An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation (GENPET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine if FCH-PET-CT imaging is superior to combined bone scan&#xD;
      and MRI/CT of the abdomen &amp; pelvis in detecting the increased incidence of metastasis&#xD;
      (nodal/distant outside the pelvis) in men with prostatic carcinoma with germline BRCA&#xD;
      mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Sensitivity of FCH-PET-CT scan</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
    <description>To determine if the sensitivity of FCH-PET-CT is superior to combined conventional imaging (MRI (T2 and T1 weighted)/CT and bone scan) in detecting nodal and distant (outside the pelvis) metastases in BRCA1/2 germline mutation carriers with prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Outline the Specificity of the FCH-PET-CT scan</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
    <description>determining the positive predictive value (PPV) and negative predictive value (NPV) in detecting metastatic disease in BRCA mutation carriers with prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3.Incidence and sites of additional metastases identified on FCH-PET-CT compared with combined MRI/bone scan.</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4.To measure the impact of FCH-PET-CT findings in changing patient management and in clinical decision making</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To investigate the rate of incidentally detected second primary tumours in BRCA mutation carriers with prostate cancer</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the prognostic significance of FCH-PET-CT findings (e.g. employing standard SUV parameters and heterogeneity of PET texture of the primary prostate tumour)</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To assess agreement between imaging readers in assessing FCH-PET-CT scans.</measure>
    <time_frame>Within 12 months of the last FCH-PET-CT scan</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <arm_group>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <description>Newly diagnosed with prostate cancer (any Gleason score, any stage, any PSA)&#xD;
Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy&#xD;
Patients on active surveillance, with a PSA doubling time of 6 months or less</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI pelvis or CT imaging</intervention_name>
    <description>Individuals to undergo a MRI or CT scan of Pelvis</description>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <other_name>Magnetic resonance imaging or computerized axial tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole body bone scan imaging</intervention_name>
    <description>bone scan of the whole body.</description>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <other_name>Bone scintigraphy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FCH-PET-CT imaging</intervention_name>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <other_name>18F Choline positron emission tomography /computerized axial tomography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient that meets the eligibility criteria and a patient at the Royal Marsden&#xD;
        Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed pathogenic germline mutation in either BRCA1 or BRCA2&#xD;
&#xD;
          -  Over the age of 18&#xD;
&#xD;
          -  Diagnosed with prostate cancer and at a time when staging imaging is clinically&#xD;
             indicated; either:&#xD;
&#xD;
               -  At a new diagnosis&#xD;
&#xD;
               -  Biochemically progressing patients who were treated radically with surgery or&#xD;
                  radiotherapy (more than 6 months ago) and are currently not receiving hormonal&#xD;
                  treatment or chemotherapy&#xD;
&#xD;
               -  Patients on active surveillance with a PSA doubling time of 6 months or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of other malignancy (excluding basal cell cancer/squamous cell cancer of the&#xD;
             skin) within five years of diagnosis&#xD;
&#xD;
          -  Known metastatic prostate cancer, both local and distant&#xD;
&#xD;
          -  Patients who have received any oncological treatment within the last six months&#xD;
&#xD;
          -  Patients on any investigational drug treatment&#xD;
&#xD;
          -  Patients on steroids&#xD;
&#xD;
          -  Known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis,&#xD;
             inflammatory bowel disease)&#xD;
&#xD;
          -  Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers,&#xD;
             aneurysm clips, claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalind A Eeles, FRCP FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cancer Research and Royal Marsden Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosalind A Eeles, FRCP FRCR</last_name>
    <phone>44 208 661 3642</phone>
    <email>rosalind.eeles@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth K Bancroft, PhD</last_name>
    <phone>44 207 808 2136</phone>
    <email>elizabeth.bancroft@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Genetics Unit, Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <state>Sutton, Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalind Eeles, MA; PhD; FRCP; FRCR; FMedSci</last_name>
      <phone>44 208 661 3642</phone>
      <email>rosalind.eeles@icr.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth K Bancroft, PhD</last_name>
      <phone>44 207 808 2136</phone>
      <email>elizabeth.bancroft@icr.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FCH-PET-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Anonymised data may be applied for via the Study Team</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

